Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) EBIT: 2020-2023

Historic EBIT for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$58.4 million.

  • Immuneering's EBIT fell 16.57% to -$16.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$58.4 million, marking a year-over-year decrease of 12.89%. This contributed to the annual value of -$58.4 million for FY2023, which is 12.89% down from last year.
  • According to the latest figures from FY2023, Immuneering's EBIT is -$58.4 million, which was down 12.89% from -$51.7 million recorded in FY2022.
  • Immuneering's EBIT's 5-year high stood at -$17.1 million during FY2020, with a 5-year trough of -$58.4 million in FY2023.
  • Moreover, its 3-year median value for EBIT was -$51.7 million (2022), whereas its average is -$48.0 million.
  • Data for Immuneering's EBIT shows a maximum YoY tumbled of 98.37% (in 2021) over the last 5 years.
  • Immuneering's EBIT (Yearly) stood at -$17.1 million in 2020, then slumped by 98.37% to -$33.9 million in 2021, then slumped by 52.70% to -$51.7 million in 2022, then dropped by 12.89% to -$58.4 million in 2023.